In general, these studies have shown that acquired non-recurrent submicroscopic variations are frequent in patients with de novo AML, many of them involving disease-relevant genes, such as TP53 or FLT3. In addition, some of these studies have observed a negative effect on the outcome of these patients, but not in a homogenous manner. Here, FLT3 is linked to acute myeloid leukemia.